

Table 5. Fourth-line and Fifth-line cost consequence analyses

	Panitumumab Intervention	Regorafenib Comparator 4th line	Best supportive care Comparator 5th line
Costs/resource use			
Medicine acquisition	¶¶¶	¶¶¶	
Administration	£3,400		
ctDNA screening	£250		
Best supportive care	£2,326	£1,089	£1,038
total	¶¶¶	¶¶¶	¶¶¶
Net cost		¶¶¶	¶¶¶
Clinical outcomes			
Overall survival (months)		5.76	8.67
Progression free survival (months)		1.74	NA
Adverse events ≥ grade 3		-29.6%	NA
¶¶¶ commercial in confidence figure removed			